TMC 114

Known as: 114, TMC, TMC-114, TMC114 
 

Topic mentions per year

Topic mentions per year

2003-2015
0102020032015

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2011
2011
Drug resistant mutations have severely restricted the success of HIV therapy. These mutations frequently involve the aspartic… (More)
Is this relevant?
Highly Cited
2008
Highly Cited
2008
BACKGROUND The present primary analysis of AntiRetroviral Therapy with TMC114 ExaMined In naive Subjects (ARTEMIS) compares the… (More)
  • figure 1
  • table 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
2007
2007
BACKGROUND The ongoing phase IIb POWER 1 (TMC114-C213) trial is designed to assess efficacy and safety of the protease inhibitor… (More)
Is this relevant?
2007
2007
The high incidence of cross-resistance between human immunodeficiency virus type 1 (HIV-1) protease inhibitors (PIs) limits their… (More)
  • table 1
  • table 2
  • table 3
  • figure 1
  • figure 2
Is this relevant?
2007
2007
The V82F/I84V double mutation is considered as the key residue mutation of the HIV-1 protease drug resistance because it can… (More)
  • figure 1
  • figure 2
  • figure 3
  • table 1
  • figure 5
Is this relevant?
2006
2006
The potent new antiviral inhibitor TMC-114 (UIC-94017) of HIV-1 protease (PR) has been studied with three PR variants containing… (More)
Is this relevant?
Highly Cited
2005
Highly Cited
2005
The purpose of this study was to characterize the antiviral activity, cytotoxicity, and mechanism of action of TMC114, a novel… (More)
  • figure 1
  • table 1
  • table 3
  • table 2
  • figure 2
Is this relevant?
2005
2005
The screening of known HIV-1 protease inhibitors against a panel of multi-drug-resistant viruses revealed the potent activity of… (More)
Is this relevant?
Highly Cited
2004
Highly Cited
2004
TMC114, a newly designed human immunodeficiency virus type 1 (HIV-1) protease inhibitor, is extremely potent against both wild… (More)
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • table 2
Is this relevant?
Highly Cited
2003
Highly Cited
2003
We designed, synthesized, and identified UIC-94017 (TMC114), a novel nonpeptidic human immunodeficiency virus type 1 (HIV-1… (More)
  • figure 1
  • table 1
  • table 2
  • table 5
Is this relevant?